A Phase 3 interventional study of Triamcinolone Acetonide and Grid laser in Diabetes Mellitus and Macular Edema, sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. Completed at 7 sites in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-14.
Sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.
Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 123rd largest by planned enrollment of the 211 interventional ones that give a count, is one of 8 that started in 2006, is one of 94 in phase 3, and was the 18th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:
Eduardo Luis Martín Javier · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Brazil and 8 more countries
Ages 18+
Universidad Complutense de Madrid · Sites in Spain
Ages 18–65
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 18+
Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Sites in Spain
Ages 20–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
254 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 97 · Phase 4 27
First in 1994; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 292 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 394 across the 211 interventional studies, 512 across the 42 observational. Of the 193 that completed or were terminated, 89 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
145 of 254 have an industry lead sponsor. The 10 most frequent:
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
6 of the studies in Diabetes Mellitus with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05769868Phase 3Consorcio Centro de Investigación Biomédica en Red (CIBER)Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments | 2027-03 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05243368Maimónides Biomedical Research Institute of CórdobaEvaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics | 2026-12-30 |
| NCT07463456Eduardo Luis Martín JavierInter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026) | 2027-04 |
| NCT07285330Consorci Sanitari de l'Alt Penedès i GarrafDietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 254 studies in Diabetes Mellitus with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether intravitreal injection of Triamcinolone Acetonide is effective in the treatment of Clinically Significant Diffuse Macular Edema due to Type 2 Diabetes Mellitus.
Diabetes mellitus and its complications represent nowadays an important issue in Public Health terms. The WHO expectations indicate that around 2025 the European population with diabetes will reach about 12%, and it has been estimated that the percent in the USA will be around 10% (King, 1995).
The severe complications of proliferant diabetic retinopathy and its disastrous effects on vision seem to be solved with retinal panphotocoagulation. The most relevant issue regarding diabetes´ ocular complications seems to be macular edema. We define macular edema as retinal thickening between 1500 microns central to fovea. It is found in about 10% diabetics, of whom about 40% will have an important visual acuity loss (Klein, 1984) In our environment, diabetes retinopathy affects nearly 21% of all the diabetics, and among them, about 6% has a clinically significant macular edema (Lopez, 2001).
Until now the only treatment available with proved efficacy for diffuse edema was grid photocoagulation, stablished as standard treatment since the publication of results from "Early Treatment Diabetic Retinopathy Study" (Olk 1990). A maximum 3 laser treatments with 3 to 4 months intervals between treatment has been accepted.
Nevertheless, the results with the treatment haven´t been considered satisfactory as the main aim is to preserve visual function, and only 15% of the patients get any improvement (Mc Donald, 1985).
Because of that more alternatives have been studied, among them victrectomy and intraocular corticosteroyd injections. Though, vitrectomy seems to provide significative improvements only if the patient has a thickened posterior hyaloid able to make a traction over the macular area (Tachi, 1996) and that doesn´t happen in the majority of diabetic patients.
The identification of Vascular Endothelial Growth Factor (VEGF) as the main responsible agent of angiogenesis and its role in the pathogenia of diabetic macular edema has opened new approach methods in the treatment of this complication (Adamis 1994). This factor, also known as Vascular Permeability Factor (VPF), interacts with "tight junctions" of retinal endothelial cells, producing a disruption of hematoretinal barrier.
It is known that corticosteroids are not only the more powerful antiangiogenetic agents, but are also capable of reversing the effects mentioned before over the retinal endothelial by acting at phosphorilation and expression of tight-junctions´ proteins. They also inhibit VEGF expression (Fisher 2001).
It seems logical that its use has been proposed in the treatment of this diabetes complication. Though, its side effects, either local or systemical, and its intraocular biodisponibility issues have obligated the use of intravitreal administration.
In 2001 was published the first work about intravitreal triamcinolone after vitrectomy in proliferative diabetes retinopathy patients, in an attempt to reduce the inflammatory response what sometimes occurs in these patients after surgery (Jonas, 2001). A series of 29 eyes shows a good tolerance of the drug administered this way.
The next year, and after the presentation at ARVO meeting, some other authors present a prospective work without control group with 16 eyes of patients who have been injected triamcinolone acetonide after grid laser failure, applied according to ETDRS criteria. The results show a visual acuity improvemente and a reduction of macular edema evaluated with ocular coherence tomography, with an effect loss in a 6 months interval (Martidis, 2002).
Since then more clinical series have been published, but yet without any prospective, randomized and control group studies done.
These series seem to show a positive effect of triamcionlone either in 25 mg dosage (Jonas, 2002) or 4 mg dosage.
It is remarkable that the majority of the studies have been published by Heidelberg Group, although series from other authors are also being published (Massin, 2004).
There has also been published side effects as ocular hypertension and endophthalmitis, that seem not to be infectious in the majority of the cases (Roth, 2003) but due to its high prevalence they need to be studied in depth.
This approach is being taken by some pharma industries with variations; intraocular controlled liberation implants of fluocionola acetonide or dexametasone biodegradable implants have been developed (Jaffe 2000).
It is also being investigated the potential effect of Anecortave acetate, a cortisol derivate, and there are also some other alternatives under research: VEGF inhibitors as adaptamers, andibodies or fragments, PKC inhibitors or angiopoiteins, some of which are currently being evaluated in Phase III Clinical Trials.
Despite the lack of clinical trials similar to the one proposed here, the topic has provoked a lot of interest in the international and national ophthalmological community and there are evidences of some of these treatments being used in our country.
Comparisons:
Study Group: TRIGON DEPOT (Bristol Mayers Squibb Labs) 4 mg intravitreal injection followed by ETDRS grid laser technique.
Control Group: ETDRS grid laser technique.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triamcinolone acetonide + Grid Laser
Drug: Triamcinolone Acetonide · Procedure: Grid laser
Sham procedure + Grid laser
Procedure: Grid laser · Procedure: Sham Injection
Intravitreal Injection 4mg single dose
Also known as: Trigon Depot
Grid laser as specified in ETDRS
Simulation procedure for triamcinolone injection
Visual acuity stabilization or improvement 6 months after treatment.
Time frame: 6 months
Macular edema reduction or stabilization 6 months after treatment.
Time frame: 6 months
Safety of the treatment.
Time frame: 6 months
Tolerance of the treatment.
Time frame: 6 months
The record gives a start of Apr 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA